Mark Johnson is professor of experimental psychology and head of the psychology department at the University of Cambridge in the United Kingdom.
Mark Johnson
Professor
Birkbeck University of London
From this contributor
Autism may arise from brain’s response to early disturbances
Autism is not a developmental disorder, but rather the brain’s adaptive response to early genetic or environmental disturbances, says Mark Johnson.
Autism may arise from brain’s response to early disturbances
By
Mark Johnson
18 August 2015 | 6 min read
Executive confusion
Among siblings of children with autism, those with better prefrontal cortex functioning — observable as relatively strong executive functions for their age — are better able to compensate for atypicalities in other brain systems early in life, and are therefore less likely to receive a diagnosis of autism later in their development, argues Mark H. Johnson.
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read